Manic depression win cheers MediTech Media

Glaxo Wellcome has appointed MediTech Media to help recruit more patients for clinical trials into a new treatment for manic depression.

Glaxo Wellcome has appointed MediTech Media to help recruit more

patients for clinical trials into a new treatment for manic

depression.



The international account win follows a three-way pitch between MediTech

Media, Hill and Knowlton and Shire Hall Communications.



Lamotrigine is currently licensed to treat epilepsy, but will not be

approved as a treatment for manic depression until the year 2000.



’Lamotrigine is a mood stabiliser, so it was put into development as a

potential treatment for manic depression,’ said Kate Davies, associate

director at MediTech Media. ’Our programme is to recruit more patients

into the clinical trials.’



Trials are being held in 20 different countries and MediTech Media will

provide guidance and core materials to Glaxo Wellcome operators in

individual countries.



’We will be targeting lay media and medical press to get GPs and

physicians to look at patients who might be suitable,’ said Davies.



MediTech Media plans to use creative figures who suffered from manic

depression, such as Vincent van Gogh, Byron and Virginia Woolf, to

attract media attention.



’There can be a fine line between creative genius and psychiatric

illness,’ said Davies.



MediTech Media also works for Glaxo Wellcome supporting products for

epilepsy, herpes, HIV and Aids.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.